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One of the melanoma-associated antigens most
extensively studied is the core glycoprotein (Mol.
wt=250kD) of a cell membrane chondroitin sulfate
proteoglycan(Bumol&Reisfeld, 1982).Amongseveral
monoclonal antibodies that recognize this antigen
(Kantor et al., 1982) the 9.2.27 antibody (Morgan
et al., 1981), has been found to bind to tumour cells
from more than 90% of human melanomas
(Oldham et al., 1984). Although some early reports
indicated that the 9.2.27 antibody may cross-react
with some types of normal cells (Lloyd et al., 1982;
Johnson & Riethmiiller, 1982) and non-melanoma
tumours (Carrel et al., 1982; Saxton et al., 1982),
the antigen regonized by the 9.2.27 antibody has
been considered to be rather specifically expressed
in melanoma cells. Recently, the 9.2.27 antibody
has been successfully used for radioimaging of
human melanomas growing as xenografts in nude
mice (Hwang et al., 1985), and it has been
investigated for use as an in vivo carrier for toxins
(Bumol et al., 1983). Clinically, the antibody has
been employed for immunotherapeutic purposes
(Oldham et al., 1984).
During testing of the binding specificity of two
monoclonal antibodies (TP-1 and TP-3) developed
in our laboratory against human sarcoma-
associated antigens (Bruland et al., 1986), we
recently made the accidental observation that the
9.2.27 antibody, included as a supposedly negative
control, showed significant binding to several
human sarcoma cell lines, as judged by indirect
immunofluoresence on unfixed cells.
To study the reactivity of the antibody with
human sarcomas in more detail, the ability of two
sarcoma cell lines to bind 9.2.27 antibody, labelled
with 12 I by the Iodo-Gen method (Fraker &
Speck, 1978), was measured and compared to that
of FEMX melanoma cells. One non-small cell lung
cancer and 4 primary cultures of skin fibroblasts
were used as controls. It was found (Table I) that
the sarcoma cell lines bound equal or higher
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amounts of the antibody than the FEMX
melanoma line, which is known to have high levels
of the 250kD antigen (Godal et al., 1986). Further-
more, appreciable amounts of labelled antibody
were bound to cultured fibroblasts (Table I).
The binding of the 9.2.27 antibody to sarcomas
and normal connective tissues obtained directly
from patients was then examined. Table II demon-
Table I Binding of "25I-labelled 9.2.27 antibody
Bound c.p.m.
Cell-line (% oftotal)
Sarcoma 1 (OHS) 50
Sarcoma 2 (PE) 22
Melanoma (FEMX) 20
Fibroblast 1 (sarcoma patient) 24
Fibroblast 2 (sarcoma patient) 15
Fibroblast 3 (non-cancer patient) 16
Fibroblast 4 (non-cancer patient) 8
Lung cancer (SELS) 0.3a
a<0.5% bound/total is considered as negative. One ml
of a cell suspension containing 105 cells in PBS in the
presence of 1 mgml-1 human serum albumin were
incubated with lOng of labelled 9.2.27 antibody at 4°C for
2h. After washing, the cell associated radioactivity was
measured.
Table II Immunostaining with the 9.2.27 antibody on
frozen sections
Tissue No. pos./No. test.
Osteogenic sarcoma 7/9
Malignant fibrous histiocytoma 5/7
Malignant Schwannoma 2/3
Synovial sarcoma 2/2
Fibrous connective tissue 0/3
Acetone-fixed cryostat sections were incubated with
10pgml-1 of the 9.2.27 antibody for 1 h at room
temperature. After washing, bound antibody was detected
by the use of Vectastain peroxidase ABC kit, following the
manufacturer's instructions.
() The Macmillan Press Ltd., 1986840 A. GODAL et al.
strates the results of immunohistochemical studies
obtained with the antibody on acetone-fixed
cryostat sections, using the Vectastain peroxydase
ABC kit (Vector Lab. Inc., Burlingame, CA, USA).
It is seen that 7 of 9 osteosarcomas were positively
stained. Similarly, 2/3 malignant Schwannomas, 5/7
malignant fibrous histiocytomas and 2/2 synovial
sarcomas were positive, indicating that the 250kD
antigen may be widely distributed in human
sarcomas. The sections of fibrous connective
tissues, however, were not stained with the
antibody, in contrast to the finding (Table I) that
cultured fibroblasts bound fairly high amounts of
labelled antibody. Since it is known that the
expression of cellular antigens may depend on the
conditions under which the cells are growing (Hosoi
et al., 1982; Zwadlo et al., 1985), it seems
reasonable to assume that in cultured fibroblasts
the expression of the 250kD antigen may be
induced during in vitro growth.
The ability of the 9.2.27 antibody to bind to
sarcomas in vivo was studied by immunoscinti-
graphy. One jug (40 1Ci) of 131I-labelled F(ab')2-
fragments of the antibody was injected into nude
mice carrying a human osteogenic sarcoma in their
left flank and a human malignant melanoma in
their right. Scintigrams obtained 20h after injection
of the labelled antibody, showed that the radio-
activity localized even better in the sarcoma than in
the melanoma (Figure 1). In contrast, uptake of
labelled TP-l anti-sarcoma antibody was restricted
to the sarcoma xenograft (not shown).
In attempts to confirm that the antigen in
sarcoma cells and cultured fibroblasts, to which the
9.2.27 antibody binds, actually is the 250kD core
Figure 1 Immunoscintigram of a nude mouse bearing
two human osteogenic sarcoma xenografts in its left
flank and a human malignant melanoma xenograft in
its right flank. Picture taken 20h after i.v. injection of
jug (40,uCi) "3'I-labelled 9.2.27 antibody. (Posterior
view).
protein, immunoprecipitation was carried out as
described by Bumol & Reisfeld (1982) on extracts
from cells labelled for 20h with 35S-methionine
(0.1 mCiml-1). The immunoprecipitate was ana-
lyzed on a 5% polyacrylamide gel in the presence
of SDS (Laemmli, 1970). It is seen (Figure 2) that
the 9.2.27 antibody precipitates the 250kD core
protein from extracts of sarcoma cells and fibro-
blasts as well as from extracts of melanoma cells.
In addition, higher mol. wt products were precipi-
tated from all extracts. These precipitates showed,
however, different migration patterns depending
on the cell type from which they originated. This
finding probably indicates that varying amounts
of chondroitin sulfate side-chains may be associated
with the protein core in the different cells examined.
A protein of mol. wt -210kD was precipitated
from the extract of fibroblasts, presumably repre-
senting a precursor for the 250kD protein similar
to that described of Bumol et al. (1984). None
of these high mol. wt proteins was detected in the
extract from the SELS lung carcinoma cells, which
had failed to bind (Table I) labelled 9.2.27
antibody.
Interestingly, when immunoprecipitation was
carried out on spent medium obtained after
incubation of labelled sarcoma and melanoma cells
for 24h in normal medium, appreciable amounts of
the high mol. wt (HMW) proteoglycan as well as
Figure2 Autoradiograph of immunoprecipitates ob-
tained with 9.2.27 antibody on extracts from 35S-
methionine-labelled cells analyzed on a 5% poly-
acrylamide gel in the presence of SDS. 1: cultured
fibroblasts; 2: osteogenic sarcoma; 3: malignant
melanoma; 4: lung carcinoma; M: 125I-labelled mol. wt
marker (HMW, Pharmacia Fine Chemicals, Uppsala,
Sweden); DF: dye front.MELANOMA-ASSOCIATED ANTIGEN IN SARCOMAS 841
the 250kD antigen were detected (not shown),
showing that the antigen is shed by both sarcoma
and melanoma cells. This observation is in
contradiction to the findings of Bumol et al. (1984),
who in spent medium from melanoma cells were
able to detect only the HMW proteoglycan. The
discrepancy may possibly be ascribed to differences
in the experimental procedures followed, as in their
case the tumour cells were labelled with 35S-
methionine for a very short period of time (Omin).
In conclusion, the present data show that the
250kD core protein is present on the cell surface of
human sarcoma cells and cultured human fibro-
blasts as well as of malignant melanoma cells. The
demonstration here of a wider distribution of this
antigen than previously recognized raises interesting
questions as to its biological function. Moreover, it
is clear from the present findings that the 9.2.27
antibody cannot be used for diagnostic purposes to
distinguish between melanomas and sarcomas. That
the 250kD antigen was found to be expressed in
sarcomas in vivo, however, opens the possibility of
using the 9.2.27 antibody in combination with anti-
sarcoma antibodies in immunoscintigraphy and
therapy of human sarcomas.
The authors are indebted to A.C. Morgan Jr. for kindly
providing the 9.2.27 antibody. The excellent technical
assistance of Arne Skretting, Anne Pharo and Vivi
Fl0renes is gratefully acknowledged.
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